跳至主要内容
临床试验/NCT02662686
NCT02662686Unknown不适用

Randomized Multi-centric Prospective Study for the Evaluation of "MitoScore" Marker in the Diagnosis of Embryo Viability in Euploids Embryos.

Igenomix22 个研究点 分布在 1 个国家目标入组 1,718 人开始时间: 2016年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
Igenomix
入组人数
1,718
试验地点
22
主要终点
Implantation rate

研究概览

简要总结

The number of copies of mitochondrial genes (mtDNA or "MitoScore") is related to the energy supply of the embryo, which can affect its ability to implant in the maternal uterus.

The objective of this study is to analyse the potential of MitoScore before embryo transfer as a marker to identify and select the embryo with greater capacity of implantation. First of all, chromosomally normal embryos will be selected and mtDNA copies will be quantified. Finally, embryos with less copies of mtDNA will be considered for embryo transfer.

详细描述

The number of mitochondrial DNA copies (mtDNA) of a chromosomally normal embryo is related to a state of energy, which affects the ability of the embryo to implant in the maternal uterus. There is a decrease in the rate of implantation in euploid embryos containing a high number of mtDNA copies. It is known that after a certain number of mtDNA copies implantation is disrupted even in euploid embryos.

The main purpose of this study is to evaluate the possible relationship between the mtDNA content contained in developing embryos and the result of implantation in order to evaluate the potential of such relationship as a diagnostic tool.

The number of mtDNA copies present in chromosomally normal embryos will be quantified. Subsequently, the transfer of euploid embryos after the randomization will be using either routine morphological or MitoScore criteria.

Study population: women undergoing either IVF or egg donation that go through preimplantation genetic screening (PGS) for different indications, either in day 5/6 or day 3.

This is a triple blinded, randomized, prospective, clinical study where patients with embryos analyzed by PGS in blastocyst stage or day 3 and mitochondrial analysis with day 5/6 transfer, with deferred cycle for those analyzed in day 5/6 and fresh embryo transfer for those analyzed in day 3, will be randomized into two groups:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Inclusion Criteria:
  • PGS cycles for different indications
  • Maternal age: ≤40 years old (FIV/ICSI patients)
  • Maternal age: <50 years old (OVODON patients)
  • Spermatocyte concentration: > 2 million of spermatocyte/ml
  • Single embryo transfer
  • ≥ 8 oocytes MII
  • Number of Antral Follicules (AFC: ≥10 MII)

排除标准

  • Detection in the moment of inclusion or previous diagnosis of congenital uterine malformations.
  • Patients with embryo sex selection for those countries in which it is allowed.

研究组 & 干预措施

Control

Active Comparator

Embryo selection for transfer will be based initially on chromosomally normal embryos and secondly on embryo morphology criteria (specific of IVF lab, as standard practice).

干预措施: Transfer according to morphological criteria (Other)

MitoScore

Experimental

Embryo selection for transfer will be based initially on chromosomal normality and secondly on the MitoScore value, trying to transfer chromosomally normal embryos which contain the lowest number of mitochondrial DNA copies.

干预措施: Transfer according to the MitoScore results (Other)

结局指标

主要结局

Implantation rate

时间窗: 20 days

Pregnancy rate

时间窗: 12 days

次要结局

  • Miscarriage rate(9 months)
  • Ongoing pregnancy rate(9 months)

研究者

发起方
Igenomix
申办方类型
Industry
责任方
Principal Investigator
主要研究者

Antonio Diez

Product Innovation Leader

Igenomix

研究点 (22)

Loading locations...

相似试验